Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Your vote was cast
Thank you for your feedback
Thank you for your feedback
Di Stefano, Antonino
Adcock, Ian M
MetadataShow full item record
AbstractChronic obstructive pulmonary disease (COPD) is a leading cause of morbidity and mortality worldwide. Long term cigarette smoking is the cause of more than 90% of COPD in Westernized countries. However, only a fraction of chronic heavy smokers develop symptomatic COPD by the age of 80 years. COPD is characterized by an abnormal immune response in the lower airways and its progression is associated with infiltration of the lung by innate and adaptive inflammatory immune cells that form lymphoid follicles. There is growing evidence that both cellular- and antibody-mediated autoimmunity has a fundamental role in the pathogenesis of stable COPD. In particular, carbonyl-modified proteins may help to drive autoimmunity in COPD and to cause the characteristic small airways abnormalities and even contribute to the pathogenesis of pulmonary emphysema. Although direct, indirect, and circumstantial evidence of a role for autoimmunity in stable COPD patients has been identified, no cause-and-effect relationship between autoimmunity and the mechanisms of COPD has been firmly established in man. As such the potential contribution of an autoimmune response to the pathogenesis of COPD exacerbation is still being investigated and represents an area of active research. Many drugs targeting autoimmune responses are already available and the results of controlled clinical trials are awaited with great interest. The potential for measuring specific serum autoantibodies as biomarkers to predict clinical phenotypes or progression of stable COPD is promising.
CitationCaramori G., Ruggeri P., Di Stefano A., Mumby S., Girbino G., Adcock IM., Kirkham P. (2017) 'Autoimmunity and COPD: clinical implications', Chest, 153(6), pp. 1424-1431 doi: 10.1016/j.chest.2017.10.033
The following license files are associated with this item:
- Antielastin B-cell and T-cell immunity in patients with chronic obstructive pulmonary disease.
- Authors: Rinaldi M, Lehouck A, Heulens N, Lavend'homme R, Carlier V, Saint-Remy JM, Decramer M, Gayan-Ramirez G, Janssens W
- Issue date: 2012 Aug
- Autoantibodies in Chronic Obstructive Pulmonary Disease.
- Authors: Wen L, Krauss-Etschmann S, Petersen F, Yu X
- Issue date: 2018
- B cells in chronic obstructive pulmonary disease: moving to center stage.
- Authors: Polverino F, Seys LJ, Bracke KR, Owen CA
- Issue date: 2016 Oct 1
- High levels of lung resident CD4+CD28null cells in COPD: implications of autoimmunity.
- Authors: Hoetzenecker K, Mitterbauer A, Guenova E, Schweiger T, Altmann P, Zimmermann M, Hofbauer H, Beer L, Klepetko W, Ankersmit HJ
- Issue date: 2013 Mar
- Autoantibodies in patients with chronic obstructive pulmonary disease.
- Authors: Feghali-Bostwick CA, Gadgil AS, Otterbein LE, Pilewski JM, Stoner MW, Csizmadia E, Zhang Y, Sciurba FC, Duncan SR
- Issue date: 2008 Jan 15